Skip to main content
PMC home page
Journal of Medical Case Reports logoLink to Journal of Medical Case Reports
. 2014 Jul 21;8:257. doi: 10.1186/1752-1947-8-257

Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report

Johanna Knapstein 1, Marcus A Wörns 1, Peter R Galle 1, Tim Zimmermann 1,✉
PMCID: PMC4110930  PMID: 25047566

Abstract

Introduction

Hepatitis C virus reinfection occurs universally after liver transplantation with accelerated cirrhosis rates of up to 30% within 5 years after liver transplantation. Management of hepatitis C virus reinfection is complicated by drug interactions and pre-treatment. Dual antiviral therapy with pegylated interferon and ribavirin only reaches sustained virological response rates of approximately 30% after liver transplantation. With the approval of the viral NS3/4A protease and NS5B ribonucleic acid -dependent ribonucleic acid polymerase inhibitors, combination therapy offers new therapeutic options resulting in considerably higher sustained virological response rates in the non-transplant setting. However, silibinin has also shown potent antiviral activity in non-responders to dual therapy.

Case presentation

We report the first case of antiviral therapy with pegylated interferon and ribavirin in combination with silibinin post-liver transplantation in a 50-year-old Caucasian man with genotype 3 reinfection with prior non-response.

Silibinin was administered at a dose of 20mg/kg/day intravenously for 2 weeks and continued orally for 47 weeks in combination with a 48-week pegylated interferon and ribavirin therapy (180μg/week and 800mg/day), which was started on day 8. Pegylated interferon and ribavirin doses were adapted to 135μg/week and 600mg/day. After 4 weeks of therapy, the viral load declined 6 log10 and became undetectable in week 6, resulting in a sustained virological response 24 weeks after the end of therapy.

In general, antiviral therapy was well tolerated. Side effects included pruritus and anaemia leading to erythropoietin therapy.

Conclusions

Combination therapy with pegylated interferon, ribavirin and silibinin resulted in sustained virological response 24 weeks after the end of therapy in a patient reinfected with hepatitis C virus genotype 3 who was a prior non-responder after liver transplantation. Silibinin therapy may offer a new therapeutic option for patients reinfected with non-genotype 1 hepatitis C virus who have had a liver transplanted and are non-responders.

Keywords: Antiviral therapy, Liver transplantation, Silibinin

Introduction

Hepatitis C virus (HCV) reinfection occurs universally after liver transplantation (LT) [1]. Under immunosuppression, the time course of recurrent HCV is accelerated, with cirrhosis rates of up to 30% within 5 years of LT [2]. So far, antiviral therapy has been limited to a combination of pegylated interferon (peg-IFN) and ribavirin (RBV) with sustained virological response (SVR) rates of approximately 30% post-LT [3-5]. With the approval of the viral NS3/4A protease inhibitor (PI) simeprevir and NS5B ribonucleic acid (RNA)-dependent RNA polymerase inhibitor (RdRpI) sofosbuvir, combination therapy offers new therapeutic options resulting in considerably higher SVR rates of 66% and 75% in treatment-naïve patients infected with HCV genotype 1 in the non-transplant setting [6,7]. However, the management of HCV reinfection after LT is complicated by drug interactions, tolerability and pre-treatment [8,9]. Therefore an individual treatment regimen is often required. However, PI-based triple therapy is limited to patients infected with HCV genotype 1. To date, very few data exist on the treatment of recurrent non-genotype 1 HCV-infection after LT.

As silibinin has been shown to be a potent antiviral agent in prior non-responders to dual therapy [10,11], we present here the first case of antiviral therapy with peg-IFN and RBV in combination with silibinin post-LT in a genotype 3 reinfected patient with prior non-response.

Case presentation

A 50-year-old Caucasian man underwent a liver transplant in 2008 due to hepatocellular carcinoma based on chronic HCV genotype 3a-associated liver cirrhosis. HCV was diagnosed in 1996. He was pre-treated with dual antiviral therapy pre-LT in 1997, resulting in primary non-response. In 2008, recurrent HCV was detected in liver biopsy. Therefore, he underwent a second attempt of dual antiviral therapy over 48 weeks, resulting in a relapse. He was referred to our LT out-patient clinic in a good state of general health (body mass index 26.2, 180cm, 85kg) with a request for antiviral therapy. HCV-RNA measured 14×106 IU/mL (COBAS® TaqMan® HCV test, version 2.0, Roche Diagnostics AG, Rotkreuz, Switzerland; lower limit of quantification: 25IU/mL; lower limit of detection: 10IU/mL). His serum transaminases were slightly elevated: alanine aminotransferase 103U/L, upper limit of normal (ULN <50IU/L; aspartate aminotransferase 114U/L, ULN 35IU/L). All other liver values were within the normal range (alkaline phosphatase, gamma-glutamyltransferase, bilirubin, international normalized ratio and albumin). Haemoglobin, leukocyte and thrombocyte counts were 16.6mg/dL, 8.6/nL and 118/nL, respectively (Figure 1). Side diagnoses included hypertension and diabetes mellitus type 2.

Figure 1.

Figure 1

Open in a new tab

Course of hepatitis C virus-ribonucleic acid (106 IU/mL), alanine aminotransferase (101U/L), haemoglobin (mg/dL), white blood cells (cells/nL) and platelets (101/nL) during therapy. After 4 weeks of therapy, viral load declined 6 log10 and became negative in week 6 resulting in SVR 24. Side effects included pruritus and anaemia, leading to the application of erythropoietin. Abbreviations: ALT, alanine aminotransferase; EOT, end-of-treatment; Hb, haemoglobin; HCV-RNA, hepatitis C virus-ribonucleic acid; PLT, platelets; SVR, sustained virological response; Tacr, tacrolimus; w, week; WBC, white blood cells.

As silibinin has shown potent antiviral activity in prior non-responders to dual therapy, informed consent was given for a triple combination therapy of silibinin, peg-IFN and RBV. He was given tacrolimus 1mg twice a day (BID) and mycophenolate-mofetil 500mg BID for immunosuppression as well as co-medication with amlodipine (5mg/day) and pantoprazole (40mg/day); insulin injections were also continued. Silibinin was administered 20mg/kg/day intravenously for 2 weeks and continued orally 560mg/day for 47 weeks in combination with a 48-week peg-IFN and RBV therapy with 180μg/week and 800mg/day started on day 8. Peg-IFN and RBV doses were adapted to 135μg/week and 600mg/day. After 4 weeks of therapy, the viral load declined 6 log10 and became undetectable in week 6, resulting in SVR 24. Therapy was well tolerated; side effects included dyspnoea, pruritus and anaemia, leading to the application of 250mg BID ursodeoxycholic acid and 30μg erythropoietin/week. Red blood cell, leukocyte and platelet counts, as well as tacrolimus through levels, were checked once a week.

Discussion

Antiviral therapy of recurrent HCV after LT is an issue of high interest and the time course of fibrosis progression is accelerated under immunosuppression [2]. Improvements in antiviral therapy are urgently required as SVR rates for dual therapy in patients who are HCV positive after LT are low [3,4]. PI and RdRpI-based combination for antiviral therapy in non-LT cohorts leads to significantly higher SVR rates compared to a dual therapy [6-10]. However, the management of HCV post-LT is complicated by drug interactions, side effects and pre-treatment [11,12].

However, PI-based triple therapy is limited to patients infected with HCV genotype 1. To date, very few data exist on the therapy of recurrent non-genotype 1 HCV-infection after LT.

In vitro experiments have shown that HCV replication is significantly inhibited by silibinin [13]. Silibinin has a strong anti-oxidative effect [14]. This may improve the response to IFN in non-responders to dual therapy since oxidative stress leads to impaired IFN signalling [15]. However, evidence for beneficial effects in humans has been equivocal. Therefore, the efficacy and safety of high-dose intravenous silibinin, followed by a lower dose oral application in combination with dual antiviral therapy, were evaluated by Ferenci et al. [16] in 2008 in chronic HCV genotype 1, 2 and 4 infected former non-responders. This study showed that silibinin is well tolerated and reveals a substantial antiviral effect against HCV in non-responders [16]. A recent study reported similar results in the transplant setting for patients reinfected with HCV genotype 1 [17]. We present here the first case of successful antiviral treatment with silibinin in combination with peg-IFN and RBV in a patient reinfected with HCV genotype 3 after LT with prior non-response to dual therapy. Treatment with silibinin might result in an IFN-sensitising effect in IFN non-responders following LT.

Conclusions

Combination therapy of peg-IFN, RBV and silibinin resulted in SVR 24 in a patient who had a liver transplanted, who was reinfected with HCV genotype 3 and who was therapy naïve. Combination therapy with silibinin might be a useful approach for the therapy of recurrent non-genotype 1 HCV infection after LT.

Consent

Written informed consent was obtained from the patient for publication of this case report and the accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations

BID: Twice a day; HCV: Hepatitis C virus; LT: Liver transplantation; peg-IFN: Pegylated interferon; PI: Protease inhibitor; RBV: Ribavirin; RdRpI: RNA-dependent RNA polymerase inhibitor; RNA: Ribonucleic acid; SVR: Sustained virological response; ULN: Upper limit of normal.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

JK collected the data and drafted the manuscript. PRG, MAW and TZ conceived of the case, and participated in therapy design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Contributor Information

Johanna Knapstein, Email: johanna.knapstein@unimedizin-mainz.de.

Marcus A Wörns, Email: marcus-alexander.woerns@unimedizin-mainz.de.

Peter R Galle, Email: peter.galle@unimedizin-mainz.de.

Tim Zimmermann, Email: tim.zimmermann@unimedizin-mainz.de.

Acknowledgements

The authors received lecture fees and travel grants from Roche, Janssen and MSD.

References

  1. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, Rodes J. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35:680–687. doi: 10.1053/jhep.2002.31773. [DOI] [PubMed] [Google Scholar]
  2. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008;14:36–44. doi: 10.1002/lt.21646. [DOI] [PubMed] [Google Scholar]
  3. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49:274–287. doi: 10.1016/j.jhep.2008.05.002. [DOI] [PubMed] [Google Scholar]
  4. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006;6:1586–1599. doi: 10.1111/j.1600-6143.2006.01362.x. [DOI] [PubMed] [Google Scholar]
  5. Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, Leandro G, Patch D, Burroughs A. Pegylated interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat. 2008;15:699–709. doi: 10.1111/j.1365-2893.2008.01019.x. [DOI] [PubMed] [Google Scholar]
  6. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK. SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peg-interferon alpha-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2011;376:705–716. doi: 10.1016/S0140-6736(10)60934-8. [DOI] [PubMed] [Google Scholar]
  7. Jacobson IM, McHutchinson JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416. doi: 10.1056/NEJMoa1012912. [DOI] [PubMed] [Google Scholar]
  8. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887. doi: 10.1056/NEJMoa1214853. [DOI] [PubMed] [Google Scholar]
  9. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014. in press. [DOI] [PubMed]
  10. Manns M, Poordad F, de Araujo ES A. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. J Hepatol. 2013;58:568. [Google Scholar]
  11. Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol. 2012;26:531–548. doi: 10.1016/j.bpg.2012.09.010. [DOI] [PubMed] [Google Scholar]
  12. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012;55:1620–1628. doi: 10.1002/hep.25653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signalling, and HCV infection by standardised Silymarin. Gastroenterology. 2007;132:1925–1936. doi: 10.1053/j.gastro.2007.02.038. [DOI] [PubMed] [Google Scholar]
  14. Pietrangelo A, Borella F, Casalgrandi G, Montosi G, Ceccarelli D, Gallesi D, Giovannini F, Gasparetto A, Masini A. Antioxidant activity of silibinin in vivo during long-term iron overload in rats. Gastroenterology. 1995;109:1941–1949. doi: 10.1016/0016-5085(95)90762-9. [DOI] [PubMed] [Google Scholar]
  15. Di Bona D, Cippitelli M, Fionda C, Cammà C, Licata A, Santoni A, Craxì A. Oxidative stress inhibits IFN-induced antiviral gene expression by blocking the JAK-STAT pathway. J Hepatol. 2006;45:271–279. doi: 10.1016/j.jhep.2006.01.037. [DOI] [PubMed] [Google Scholar]
  16. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schöniger-Hekele M, Holzmann H, Steindl-Munda P. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008;135:1561–1567. doi: 10.1053/j.gastro.2008.07.072. [DOI] [PubMed] [Google Scholar]
  17. Eurich D, Bahra M, Berg T, Boas-Knoop S, Biermer M, Neuhaus R, Neuhaus P, Neumann U. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in non-responders to pegylated interferon-based therapy. Exp Clin Transplant. 2011;9:1–6. [PubMed] [Google Scholar]

Articles from Journal of Medical Case Reports are provided here courtesy of BMC

RESOURCES